In this section
The Network aims to promote multi-disciplinary approaches to address challenging vaccine-related questions. This page contains a curated list of publications that highlight high-impact and collaborative approaches.
@article{Reglinski:2016:10.1016/j.jinf.2016.02.002,
author = {Reglinski, M and Lynskey, NN and Choi, YJ and Sriskandan, S and Edwards, RJ},
doi = {10.1016/j.jinf.2016.02.002},
journal = {Journal of Infection},
pages = {450--459},
title = {Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG},
url = {http://dx.doi.org/10.1016/j.jinf.2016.02.002},
volume = {72},
year = {2016}
}
TY - JOUR
AB - ObjectivesDespite over a century of research and the careful scrutiny of many promising targets, there is currently no vaccine available for the prevention of Streptococcus pyogenes infection. Through analysis of the protective, anti-streptococcal components of pooled human immunoglobulin, we previously identified ten highly conserved and invariant S. pyogenes antigens that contribute to anti-streptococcal immunity in the adult population. We sought to emulate population immunity to S. pyogenes through a process of active vaccination, using the antigens targeted by pooled human immunoglobulin.MethodsSeven targets were produced recombinantly and mixed to form a multicomponent vaccine (Spy7). Vaccinated mice were challenged with S. pyogenes isolates representing four globally relevant serotypes (M1, M3, M12 and M89) using an established model of invasive disease.ResultsVaccination with Spy7 stimulated the production of anti-streptococcal antibodies, and limited systemic dissemination of M1 and M3 S. pyogenes from an intramuscular infection focus. Vaccination additionally attenuated disease severity due to M1 S. pyogenes as evidenced by reduction in weight loss, and modulated cytokine release.ConclusionSpy7 vaccination successfully stimulated the generation of protective anti-streptococcal immunity in vivo. Identification of reactive antigens using pooled human immunoglobulin may represent a novel route to vaccine discovery for extracellular bacteria.
AU - Reglinski,M
AU - Lynskey,NN
AU - Choi,YJ
AU - Sriskandan,S
AU - Edwards,RJ
DO - 10.1016/j.jinf.2016.02.002
EP - 459
PY - 2016///
SN - 1532-2742
SP - 450
TI - Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG
T2 - Journal of Infection
UR - http://dx.doi.org/10.1016/j.jinf.2016.02.002
UR - http://hdl.handle.net/10044/1/29618
VL - 72
ER -
Clinical Senior Lecturer
Dr Christopher Chiu
vaccine.network@imperial.ac.uk
+44 (0)20 8383 2301
